- Navrogen Enters Into CRADA With USAMRIID To Test Proprietary Small Molecule NK Cell Activators Against SARS-COV-2 InfectionSeptember 13, 2021Navrogen announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at The United States Army Medical Research Institute of Infectious Diseases (USAMRIID). The CRADA is focused on testing Navrogen's small molecule NK cell activating agents on suppressing propagation of SARS-COV-2. [read more]
- Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline AgentsAugust 17, 2021Navrogen and Tavotek will collaborate on the development of future Tavotek oncology assets while utilizing Navrogen’s proprietary screening technology to identify mAb leads that are susceptible to Humoral Immuno-Oncology (HIO) factors. The teams will identify and/or engineer HIO-refractory antibodies that are effective across a wide range of HIO-positive cancers [read more]
- Navrogen Closes $3.0M Seed Financing to Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers and Immune-Related DisordersAugust 9, 2021Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has raised $3.0M from an equity financing to support its Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. HIO is a process by which tumors produce factors that suppress a patient’s humoral immune response against malignant tissues. [read more]
- Navrogen Signs Commercial Evaluation License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immunosuppressed CancersJuly 1, 2021Navrogen has signed a commercial evaluation license agreement with the National Cancer Institute (NCI) of the National Institutes of Health (NIH) for the commercialization of tumor targeted therapies to treat humoral immunosuppressed cancers using recombinant Pseudomonas exotoxin A (PE)-containing immunotoxins having reduced immunogenicity. [read more]
- Navrogen Establishes Research Collaboration with The National Cancer Institute to Test Mesothelin-Targeting Therapies for Cancers Affected by Humoral Immuno-Oncology FactorsJanuary 11, 2021Navrogen, Inc. and the National Cancer Institute (NCI), part of the National Institutes of Health, have established a research collaboration aimed at testing mesothelin-targeting therapies for the treatment of cancers where humoral immunity is suppressed. [read more]
- Navrogen Signs Commercial License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immuno-suppressed CancersSeptember 29, 2020Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the commercialization of mesothelin-targeting agents. [read more]
- Navrogen Awarded National Cancer Institute Grant to Develop Next-Generation Rituximab with Enhanced Therapeutic EffectsSeptember 14, 2020Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced today that it has been awarded a National Cancer Institute (NCI) R03 Grant to support its NAV-006 program involving the development of a next-generation rituximab that is refractory to the immuno-suppressive effects of the tumor microenvironment. [read more]
- Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates to Treat Humoral Immuno-Suppressed CancersFebruary 4, 2020Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, a company specialized in developing antibody drug conjugates (ADCs), announced today the expanded collaboration to develop ADCs targeting humoral immuno-suppressed cancers. [read more]
- Navrogen Opens R&D Operations at Cheyney UniversityJanuary 31, 2020Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced the opening of its R&D operations at the Cheyney University science center located in Chester County, PA. The move enables the company to expand its proprietary Humoral Immuno Oncology (HIO) technology discovery efforts. [read more]
- Navrogen Inc. and Lonza Sign Agreement to Use Lonza’S GS Gene Expression System® for Navrogen’s Anti-HIO Targeting AgentsNovember 20, 2019Navrogen Inc. and Lonza Pharma & Biotech announced today that they have entered a licensing agreement for the production of Navrogen's biotherapeutics using Lonza’s GS Xceed Expression System. Navrogen recently announced funding to develop biotherapeutics targeting Humoral Immuno-Oncology (HIO) factors to reverse their inhibitory activity against the pharmacologic effects of antibody-based therapies. [read more]
- Navrogen Enters into CRADA with the U.S. National Cancer Institute to Develop Agents to Overcome Tumor-Mediated ImmunosuppressionOctober 1, 2019Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI). The CRADA is focused on advancing antibody-based experimental medicines to targets associated with tumor-mediated immunosuppression. [read more]
- Navrogen Announces the Closing of $3.2M Funding to Support its Humoral Immuno-Oncology Platform Discovery Technologies and Preclinical PipelineSeptember 17, 2019Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors. [read more]